Skip to main content
. 2013 Dec 21;129(3):143–153. doi: 10.1111/ane.12207

Figure 3.

Figure 3

Oxtellar XR (SPN-804) vs placebo: Median percent reduction from baseline 28-day seizure frequency in the North American cluster of study sites (A) and Eastern Europe/Russia cluster (B) in the ITT population. *= 0.02; **= 0.006 vs placebo. ITT, intent-to-treat.